FindTrial
Sign In

A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia

A Phase III Clinical Trial of Duloxetine in Participants With Fibromyalgia

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221737
Enrollment
Unknown
Registered
2012-03-08
Start date
2012-03-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Interventions

investigational material(s) Generic name etc : Duloxetine Hydrochloride INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Admi

Sponsors

SHIONOGI & CO., LTD.
Lead Sponsor
Eli Lilly and Company
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants fulfilling the criteria in the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. And et al.

Exclusion criteria

Exclusion criteria: Participants with past history of multiple episodes of drug allergy. Participants previously treated with duloxetine. And et al.

Design outcomes

Primary

MeasureTime frame
Change from baseline in Brief Pain Inventory (BPI)-average pain score—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026